Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib for HRR-mutated solid tumors
NCT04171700Phase 2Terminated
- Sponsor
- pharma&
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rucaparib in solid tumor, sponsored by pharma&. Primary endpoint: Best Overall Response Rate by Investigator up to 2 years. Started Jan 2020; status: terminated.
02
Drugs
rucaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04171700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171700.